Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy121% reduction ...

Basel, 13 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, announced today ...

while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous injection and Perjeta as an intravenous infusion, says the CHMP. According to the ...

7,3 About Phesgo® (pertuzumab, trastuzumab, and hyaluronidase subcutaneous (SC)) Phesgo is a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, ...

“Adding Perjeta to a standard adjuvant treatment ... dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa ...

Conversion from Perjeta to Phesgo is ongoing ... pre-filled syringe is approved as a 20 to 30 second subcutaneous injection, which is administered by a patient, a caregiver or a healthcare ...

Similarly, Phesgo, Roche’s subcutaneous formulation of Perjeta and Herceptin for HER2-positive breast cancer, achieved first quarter 2025 revenue of approximately $675 million, representing 52% ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast cancer. Now, the company can further back up the regimen’s prowess ...

The APHINITY study confirmed significant overall survival benefits of a Perjeta-based regimen in HER2-positive early-stage breast cancer, especially for lymph node-positive patients. Ten-year data ...

Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy 1 Data to ...

91.6% of patients on Perjeta-based therapy are alive at 10 years vs. 89.8% with the standard regimen. 21% reduced death risk in node-positive subgroup, confirms prior invasive disease-free ...